Bengaluru, February 6, 2025: Emcure Pharmaceuticals Ltd. (BSE:544210, NSE: EMCURE) today announced its unaudited consolidated financial results for the quarter ended December 31^st, 2024.

The quarter saw strong growth led by the International businesses that grew 23% YoY. The Canadian business continues to perform well, achieving a 34% YoY growth and the Mantra subsidiary is now fully integrated. Company’s Rest of the World (RoW) market business grew a robust 40% YoY aided by strong growth in our non-ARV segment. The company continues to see traction in its key focus markets led by its differentiated product portfolio. Emcure’s Domestic business grew by over 12% to ₹ 888 Cr, led by a steady performance in the base business and aided by in-licensed products.

Commenting on the results, Satish Mehta, CEO and Managing Director, Emcure Pharmaceuticals Ltd., said, “Emcure witnessed a strong performance in Q3. Our International business is seeing strong performance on back of our differentiated product portfolio. On the domestic side, our focus is on expanding our covered market through differentiated product launches and driving synergies from the in-licensed Sanofi portfolio. Moving forward, we aim to enhance our organic growth and margins through new product launches and operating efficiencies.”

Revenue break-up:

Contd.
Performance Summary (Consolidated)

The post Emcure Pharmaceuticals Announces Strong Q3FY25 with 18% Revenue Growth and 30% Profit After Tax Growth appeared first on newsmantra.in l Latest news on Politics, World, Bollywood, Sports, Delhi, Jammu & Kashmir, Trending news | News Mantra.

Bengaluru, November 7, 2024: Emcure Pharmaceuticals (BSE:544210, NSE: EMCURE) today announced its unaudited consolidated financial results for the quarter ended September 30^th, 2024. The company demonstrated strong performance across geographies, achieving robust revenue and profit growth.

The quarter saw strong growth especially in the International businesses that grew 25% YoY and 18% QoQ. The Canadian business continued to perform well, achieving a 51% YoY growth, driven by robust growth in our base business and our subsidiary, Mantra. The Rest of the world market business grew 29% YoY aided by strong growth in both ARV and Non-ARV segment. The company continues to see strong traction in its key focus markets. Europe experienced steady growth of 6%, driven by an increase in our base business. Emcure’s Domestic business grew by over 15% to ₹ 933 Cr, led by a steady performance in our base business and further aided by Sanofi distribution agreement.

Commenting on the results, Satish Mehta, CEO and Managing Director, Emcure Pharmaceuticals Ltd., said, “Emcure witnessed a strong performance in Q2. We have made significant investments in both our International and Domestic businesses over the past 2 years and the benefits of these efforts are starting to particularly reflect in the growth of our International business. Our recent inorganic additions – Sanofi partnership in India and Mantra acquisition in Canada – are now fully integrated and our focus is now on deriving both revenue and operational synergies. Moving forward, we aim to enhance the margins by leveraging operating efficiencies, while continuing to drive strong growth in both Indian and International markets through new product launches and market share gains.”

Revenue break-up: 

Performance Summary (Consolidated) 

The post Emcure Pharmaceuticals Announces Strong Q2FY25 with 20% Revenue Growth and 38% Profit After Tax Growth  appeared first on newsmantra.in l Latest news on Politics, World, Bollywood, Sports, Delhi, Jammu & Kashmir, Trending news | News Mantra.